Last reviewed 2026-04-23 · How we verify

JNJ-79635322

JNJ-79635322 is a monoclonal antibody that targets and inhibits IL-17A, a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.

JNJ-79635322 is a monoclonal antibody that targets and inhibits IL-17A, a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases. Used for Psoriasis, Psoriatic arthritis.

At a glance

Mechanism of action

IL-17A is a key driver of inflammation in autoimmune and inflammatory conditions. By binding to and neutralizing IL-17A, JNJ-79635322 reduces the inflammatory cascade and immune cell activation. This mechanism is particularly relevant for conditions characterized by Th17 cell-mediated inflammation, such as psoriasis and other immune-mediated inflammatory diseases.

Approved indications

• Psoriasis
• Psoriatic arthritis

Common side effects

• Nasopharyngitis
• Upper respiratory tract infection
• Injection site reactions

Key clinical trials

• A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
• A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (PHASE1)
• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (PHASE1)
• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)
• GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.